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Descartes-Sorbonne Cité University, Paris, FranceX-linked severe combined immunodeficiency (SCID-X1) is
caused by mutations in the interleukin-2 receptor g chain
gene (IL2RG), and it is characterized by profound defects in
T, B, and natural killer (NK) cell functions. Transplantation
of hematopoietic stem/progenitor cells (HSPCs) genetically
corrected with early murine leukemia retrovirus (MLV)-
derived gammaretroviral vectors showed restoration of T cell
immunity in patients, but it resulted in vector-induced inser-
tional oncogenesis. We developed a self-inactivating (SIN) len-
tiviral vector carrying a codon-optimized human IL2RG cDNA
driven by the EF1a short promoter (EFS-IL2RG), and we tested
its efficacy and safety in vivo by transplanting transduced Il2rg-
deficient Lin HSPCs in an Il2rg//Rag2/ mouse model.
The study showed restoration of T, B, and NK cell counts in
bone marrow and peripheral blood and normalization of
thymus and spleen cellularity and architecture. High-definition
insertion site analysis defined the EFS-IL2RG genomic integra-
tion profile, and it showed no sign of vector-induced clonal se-
lection or skewing in primarily and secondarily transplanted
animals. The study enables a phase I/II clinical trial aimed at
restoring both T and B cell immunity in SCID-X1 children
upon non-myeloablative conditioning.Received 21 October 2017; accepted 6 March 2018;
https://doi.org/10.1016/j.omtm.2018.03.002.
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Transplantation of autologous hematopoietic stem/progenitor cells
(HSPCs) genetically corrected with a retroviral vector has been
clinically tested as a treatment for four primary immunodeficiencies
(PIDs), i.e., adenosine deaminase-deficient severe combined immu-
nodeficiency (ADA-SCID), X-linked SCID (SCID-X1), Wiskott-
Aldrich syndrome (WAS), and X-linked chronic granulomatous
disease (X-CGD), each presenting different challenges in terms of
achieving optimal correction and clinical efficacy.1 The first clinical
trials were based on vectors derived from the Moloney murine leuke-
mia retrovirus (MLV), carrying a therapeutic gene under the control
of the MLV long terminal repeat (LTR) promoter/enhancer.2–7
Although this form of gene therapy has been beneficial for most pa-
tients, all trials except those for ADA-SCID were characterized by se-
vere adverse events, i.e., the occurrence of leukemia or myelodysplasiaMolecular Therapy: Methods
This is an open access article under the CC BY-NC-promoted by the insertional activation of proto-oncogenes (LMO2,
CCND2, and MECOM) by the MLV vector.1 The molecular basis
of these events is still ill defined, though it is likely that insertional
deregulation of one or more proto-oncogenes led to clonal expansion
and eventually transformation of HSPCs, a major genotoxic
consequence of the genetic modification intended to correct the
immunodeficiency.8,9
The recognition of the MLV LTR as a major component contributing
to the insertional gene activation led to the design of self-inactivating
(SIN) gammaretroviral vectors, which do not contain the LTR pro-
moter/enhancer sequences and instead incorporate mammalian pro-
moters devoid of long-range acting enhancers to drive the expression
of the therapeutic gene. This vector design proved safe and efficacious
in one clinical trial of gene therapy for SCID-X1.10 However, LTR
modifications do not change the overall retroviral vector target site se-
lection,11 which is directed by the interaction of theMLV pre-integra-
tion complex with acetylated, active transcriptional control elements
in the host cell genome.12
To overcome the risk of insertional oncogenesis, a new generation of
vectors, derived from the human immunodeficiency lentivirus HIV-1,
has largely replaced MLV-derived vectors in clinical trials involving
genetically modified HSPCs. The integration pattern of lentiviral vec-
tors (LVs) is inherently safer than that ofMLV vectors, as indicated by
in vitro as well as in vivo studies.13,14 LVs preferentially integrate
throughout the transcribed portion of active genes, targeting at
high-frequency genes located in the outer portion of the nucleus in
proximity to the nuclear pore,15 with no preference for regulatory
elements or specific gene categories.8,12,16 LVs have been used
to transduce HSPCs in clinical trials of gene therapy for WAS,17,18& Clinical Development Vol. 9 June 2018 ª 2018 The Authors. 257
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Methods & Clinical Developmentadrenoleukodystrophy (ALD),19 metachromatic leukodystrophy
(MLD),20 and hemoglobinopathies,21,22 providing strong evidence
of clinical efficacy in the absence of treatment-related adverse events.
Early data indicate the potential of LVs also for gene therapy of
SCID-X1.23
Here we report a pre-clinical study addressing the efficacy and safety
of gene therapy for SCID-X1 by transplantation of HSPCs transduced
by a lentiviral vector. SCID-X1 is caused by mutations in the gene
encoding the interleukin-2 receptor g chain (IL2RG), and it is char-
acterized by a lack of response to common g chain-dependent cyto-
kines and profound defects in T, B, and natural killer (NK) cell func-
tions.24 Early clinical studies based on HSPCs genetically corrected
with MLV or SIN-MLV vectors expressing IL2RG in non-condi-
tioned patients showed long-lasting restoration of T cell immunity,
though not of B or NK cells, despite the high frequency of severe
adverse events observed with the use of MLV vectors carrying wild-
type LTRs.25,26 To develop a safer alternative to MLV vectors, we
developed a third-generation lentiviral vector carrying a codon-opti-
mized human IL2RG cDNA27 under the control of the human short
elongation factor 1a (EFS) promoter. The performance of the vector
was demonstrated in vitro by the restoration of a normal level of
IL2RG mRNA or protein in a human IL2RG-deficient T cell line
and by high-efficiency transduction of human-mobilized CD34+
HSPCs. The in vivo safety and efficacy were tested in a preclinical
model of SCID-X1 gene therapy based on transplantation of geneti-
cally corrected Lin cells from IL2rg/ donor mice into sub-lethally
irradiated IL2rg//Rag2/ recipients. The vector genotoxic profile
was investigated by an in vitro immortalization assay (IVIM)28 and
in vivo by insertion site analysis, in pre-transplant Lin cells and in
bone marrow (BM), thymus, and peripheral blood (PB) of trans-
planted mice, to detect the presence of any clonal skewing or any de-
viation from a normal lentiviral integration pattern. These studies
enable a phase I/II clinical trial aimed at establishing the safety of
lentiviral vector-mediated gene therapy for SCID-X1 after non-mye-
loablative marrow conditioning and its efficacy in achieving sustained
restoration of T, B, and NK cell immunity.
RESULTS
Design of a SIN Lentiviral Vector for SCID-X1 Gene Therapy
A SIN lentiviral vector was constructed by cloning a codon-optimized
IL2RG cDNA sequence (IL2RGco), encoding the interleukin-2 recep-
tor (IL2R) common g chain under the transcriptional control of the
EFS promoter and the mutatedWPRE* in the CCL-SIN-18 LV vector
backbone (EFS-IL2RG; Figure S1A). The efficiency of the VSV-G-
pseudotyped EFS-IL2RG vector in driving IL2RGmRNA and protein
expression was tested in a human leukemic T cell line lacking endog-
enous g chain expression (ED7R cells) and compared to an identical
vector containing the cDNA for the native (wild-type [WT]) sequence
of the human IL2RG. ED7R cells were transduced with both vectors at
increasing MOIs (0.1–100) and maintained in liquid culture for
12 days before evaluating IL2RG mRNA and protein expression.
IL2RGco mRNA level in transduced cells was measured by qRT-
PCR, normalized to a housekeeping gene (TFIID), and expressed as258 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20fold change with respect to the constitutively expressed, endogenous
IL2RG mRNA in the Jurkat T cell line. IL2RG protein expression was
evaluated by flow cytometry after staining with an anti-human g
chain-specific antibody (anti-CD132). The EFS-IL2RG vector drove
significantly higher expression (t test, p < 0.05) of IL2RG mRNA
and protein with respect to the vector containing the WT IL2RG
sequence (Figures S1B and S1C). Transduction efficiency of EFS-
IL2RG in human HSPCs was determined by transducing cord
blood CD34+ cells derived from 5 different donors. HSPCs were
transduced at increasing MOIs (10, 50, and 100) and maintained in
liquid culture for 8 days or cultured as individual progenitors
(colony-forming cells [CFCs]) in semi-solid medium for 2 weeks.
The average vector copy number (VCN) in the bulk population of
transduced CD34+ cells was 0.6 ± 0.1, 1.8 ± 0.5, and 2.8 ± 0.7
(mean ± SD), respectively, while the percentage of transduced
individual CFCs (myeloid + erythroid + mixed colonies) was
54% ± 34%, 83% ± 10%, and 81% ± 7%, respectively.
Correction of the SCID-X1Phenotype by Transplantation of EFS-
IL2RG-Transduced Hematopoietic Stem Cells in Il2rg-Deficient
Mice
The efficacy of the EFS-IL2RG vector in correcting the SCID-X1
phenotype was tested in an Il2rg-deficient murine model of the dis-
ease. BM-derived lineage-negative (Lin) Il2rg/ cells frommale do-
nors of three different age groups (2–4, 5–10, and 16 weeks) were
separately transduced with one or two rounds of infection with the
EFS-IL2RG vector and transplanted into sub-lethally irradiated
Rag2//Il2rg/ female recipients (Figure 1A). The rationale for
transplanting cells from mice of different ages was to show potential
age-related differences in engrafting or reconstitution capacity of
stem cells with this disease background. Rag2//Il2rg/ mice
were used as recipients since they completely lack T, B, and NK cells,
and they represent a better, less leaky background with respect to the
Il2rg/ single knockout to study immune cell reconstitution. As
control arms, Rag2//Il2rg/ mice were transplanted with WT
C57BL/6J or Il2rg/ BM Lin cells transduced with a control lenti-
viral vector (PGK-GFP) expressing the GFP gene under the human
phosphoglycerate kinase (PGK) promoter (groups WT + PGK-GFP
and knockout [KO] + PGK-GFP in Figure 1A).
Lin cells were pre-activated overnight with a cytokine cocktail and
transduced once or twice with EFS-IL2RG or PGK-GFP at a vector
concentration of 1  108 TU/mL (MOI 400) and transplanted by
retro-orbital venous injection. An aliquot of the transduced cells
was maintained in liquid culture for a week for VCN evaluation
and vector integration analysis, or it was cultured as individual pro-
genitors in semi-solid medium for 2 weeks. In these cells, the VCN
averaged 2.5 and 4.5 after one or two rounds of transduction with
EFS-IL2RG, respectively, with 78% and 92% of transduced individual
progenitors. Vector-driven IL2RG mRNA expression ranged from
0.5- to 1.2-fold with respect to the endogenous Il2rg mRNA in WT
cells (Table 1). Overall, eight mice died or were sacrificed in the first
4 weeks after transplantation because of loss of weight or poor health,




Figure 1. Transplantation of HSPCs Transduced
with the EFS-IL2RG in Il2rg-Deficient Mice
(A) Scheme of the in vivo study. (B) Chimerism, VCN, and
VCN/donor cell in the bone marrow of Rag2//Il2rg/
mice transplanted with wild-type C56Bl6 Lin cells
transduced with a PGK-GFP vector (WT + PGK-GFP),
Il2rg/ Lin cells transduced with the PGK-GFP vector
(KO + PGK-GFP), and Il2rg/ Lin cells transduced with
the EFS-IL2RG vector (KO + EFS-IL2RG), 6 months after
transplantation. (C) Chimerism, VCN, and VCN/donor cell
in the peripheral blood of the same animals. Data are
presented as individual animals and as means ± SEM.
*p < 0.05, **p < 0.01, and ***p < 0.001.
www.moleculartherapy.orggroups. VCN, blood cell count, and immune cell phenotype were
evaluated in PB at 3 and 6 months and in the BM at 6 months. At
sacrifice, mice were also analyzed for cell engraftment and
biodistribution.
At the end of the study, donor chimerism was estimated in the BM by
qPCR analysis with donor-specific primers for the Y chromosome,
and it showed a significantly lower engraftment of Il2rg/ stem cells,
transduced by either the IL2RG or the GFP vector, with respect to
mice engrafted with WT cells (Mann-Whitney test, p value < 0.01)
(Figure 1B). No significant difference in chimerism was observed in
the PB from the same mice (Figure 1C). In the test group, the average
VCN in both the BM and PB correlated with values measured in pre-
transplant cells, and it showed efficient transduction of repopulating
stem cells by the EFS-IL2RG vector (Figures 1B and 1C). In
these mice, VCNs were on average higher in PB than in the BM
(2.04 ± 0.35 versus 1.05 ± 0.40), although the difference was border-
line significant (p = 0.07), suggesting a selective advantage in the PB of
cells expressing higher levels of IL2RG (Figure 1). Mice transplanted
with Lin cells from donors of different age showed non-significantMolecular Therapy: Methodsdifferences in engraftment and average VCN,
in both the BM and PB (data not shown). Like-
wise, no significant difference in either chime-
rism or VCN was observed in mice transplanted
with cells transduced by one or two hits of either
the test or the control vector (Figure S2). There-
fore, all transplanted mice were subsequently
analyzed as a single group.
Overall, white blood cell counts in the test group
(KO + EFS-IL2RG) were comparable to those of
mice transplanted with WT cells (WT + PGK-
GFP) and significantly higher (Mann-Whitney
test, p value < 0.001) than those of mice trans-
planted with non-corrected Il2rg/ cells
(KO + PGK-GFP). Red blood cell (RBC) and
platelet counts, Hb levels, and hematocrit
showed no difference among groups (Figure S3).
Immune reconstitution was evaluated by
immunophenotyping of the BM, PB, spleen,and thymus cells at the end of the study (Figure 2). Cells isolated
were stained with antibodies against specific surface antigens of
T cells (CD3+), thymocytes (CD4+/CD8+), B cells (CD19+), NK cells
(NK1.1+), and myeloid cells (CD11b+), and they were analyzed by
flow cytometry. In the BM, PD, spleen, and thymus of mice trans-
planted with corrected cells, T cell reconstitution was comparable
to that of mice receiving WT cells and significantly higher
than mice receiving non-corrected cells (Mann-Whitney test,
p value < 0.0001; Figure 2A), indicating that the EFS-IL2RG vector
drives robust T cell development and repopulation of lymphoid
organs. In the B and NK cell compartment, cell reconstitution was
less efficient compared to mice receiving WT cells, but it was still
significantly higher than in mice receiving non-corrected cells
(Mann-Whitney test, p value < 0.01) in all organs (Figure 2). The
restoration of a functional B cell compartment was confirmed by
the presence of immunoglobulins (IgM and IgG) in the serum of
the treated mice, at levels comparable with those of mice receiving
normal cells (Figure S4). In the thymus, the number of CD4+/CD8+
thymocytes was comparable in mice transplanted with corrected or
WT cells, while in mice receiving non-corrected cells this population& Clinical Development Vol. 9 June 2018 259










WT + GFP 3.5 ± 0.4 1 80.5 ± 0.7 88
KO + GFP 2.1 ± 0.5 – 64 ± 9 78
KO + IL2RG 1 hit 2.5 ± 1.1 0.46 ± 0.22 – 78
KO + IL2RG 2 hits 4.5 ± 1.0 1.17 ± 0.47 – 92
Molecular Therapy: Methods & Clinical Developmentwas undetectable (Figure 2C). Overall, histopathological analysis of
spleen and thymus revealed comparable size, cellularity, and organ
architecture in mice treated with either corrected or WT cells (Fig-
ure S5). No sign of malignancy was observed in mice transplanted
with corrected Il2rg/ cells, while a thymic disseminated lymphoma
was observed in a single mouse transplanted with WT cells trans-
duced by PGK-GFP.
Two individual mice in the KO + IL2RG group (169 and 170), trans-
planted with cells from 2- to 4-week-old donors, showed a population
of double-positive CD4+/CD8+ cells in the PB (25% of the total
mononuclear cells; Figure S6), but no sign of malignancy. Mouse
169 had virtually no thymus, while mouse 170 showed a thymus
with normal architecture (data not shown) and T cell counts and
phenotype indistinguishable from those of a mouse transplanted
with WT cells (Figure S6). The BMs of these animals, together with
that of a mouse from the same group that had no double-positive pop-
ulation in the periphery (179), were serially transplanted in Il2rg/
recipients (two for each donor), which were analyzed for cell pheno-
type 3 months after transplantation. None of the animals showed
signs of a double-positive T cell population in their PB (Figure S6).
Analysis of the In Vitro Genotoxic Potential of the EFS-IL2RG
Vector
We used the IVIM assay28,29 to estimate the insertional mutagenesis
potential of the EFS-IL2RG vector in vitro. Mutagenic vectors with
strong enhancer/promoter sequences can activate proto-oncogenes
near the insertion sites. In the IVIM assay, these mutants show a pro-
liferation advantage when cells are seeded at very low density. While
non-immortalized cells stop growing, insertional mutants can be
quantified by their replating phenotype on a 96-well plate. The
EFS-IL2RG vector was tested with non-transduced (MOCK) cells as
a negative control and two vectors with known mutagenic potential
as positive controls, i.e., a gammaretroviral vector with a spleen
focus-forming virus (SFFV) promoter/enhancer element in the intact
LTRs (RV.SF) and a SIN lentiviral vector with the same SFFV
elements in an internal position (LV.SF). For RV.SF, we observed
insertional mutants in 9 of 10 assays. Vector LV.SF triggered immor-
talization in 2 of 3 assays. In contrast, EFS-IL2RG had a significantly
lower incidence and fitness of insertional mutants (Figure 3): only 1 of
12 assays showed cells with a replating potential. As this phenotype is
most often elicited by an overexpression of Mecom genes, we
expanded these positive wells and performed a qPCR-based gene260 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20expression assay. We observed no upregulation of Mecom in the
EFS-IL2RG-transduced, re-plated cells, unlike the RV.SF-transduced
control clone that was expanded and measured in parallel (Table S1).
Analysis of the Integration Profile of the EFS-IL2RG Vector in
Murine Il2rg–/– Lin– Progenitors
The global integration pattern of the EFS-IL2RG vector was deter-
mined on an aliquot of the transduced Il2rg/ Lin cells. Integration
sites (ISs) were recovered by ligation-mediated PCR (LM-PCR) fol-
lowed by Illumina sequencing, and they were mapped to the mouse
genome (mm10 assembly) by a custom-designed bioinformatic pipe-
line (Figure 4A). Sequencing of the three LM-PCR libraries obtained
by transduction of Il2rg/ Lin cells of the three different age groups
generated a total of 26 million reads and 93,049 ISs univocally map-
ped on the murine genome. The EFS-IL2RG vector showed the ca-
nonical LV integration profile, with a prevalence of intragenic ISs
(72%), either intronic (67%) or exonic (5%) (Figure 4B). Virtually
all the ISs were represented by less than 1% of the total sequencing
reads, indicating a highly polyclonal composition of the original
pool of transduced Lin cells (Figure 4C). The 66,532 intragenic ISs
targeted 9,131 genes, defined as spanning from the transcription start
site (TSS) to the end of the gene. By applying a less stringent gene defi-
nition, which includes 50 kb upstream of the TSS, we identified a pool
of 16,406 targeted genes enriched in 35 gene ontology functional cat-
egories (Table S2) and 20 Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways (Table S3) by Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID) analysis (p < 0.05 after
Bonferroni correction for false discovery rate). Enriched pathways
included metabolism and transport of nucleic acids and proteins,
chromatin modifications, regulation of gene expression and mitosis,
ubiquitination, splicing, and endocytosis.
Analysis of the Integration Profile of the EFS-IL2RG Vector in the
BM and PB of Transplanted Mice
The aim of the analysis was to compare pre- and post-transplantation
integration profiles in terms of frequency and function of the targeted
gene pool that might suggest positive or negative selection of cells
harboring specific integration events. The ex vivo, post-transplanta-
tion EFS-IL2RG integration profile was determined on 14/20 mice
surviving at 6 months. The integration profile was determined in
the BM and PB of mice belonging to each transduction group as pools
(2–4, 5–10, and 16 weeks). Mice 169 and 170, showing the abnormal
CD4+/CD8+ cell population in the PB (see above), were analyzed indi-
vidually, as well as one control mouse (179) belonging to the same
transduction group (2–4 weeks), and they were excluded from the
pooled post-transplant IS datasets. Overall, we retrieved 2,525 and
2,924 post-transplant ISs from the BM and PB, respectively (merged
pool of all transduction groups). A large fraction of ISs accounted for
<1% of the total read counts in both tissues (in gray in Figure 4C), and
no IS accounted for >4.7% and >5.3% of the total reads in the BM and
PB, respectively, indicating a largely polyclonal hematopoietic recon-
stitution in the transplanted mice, although we cannot exclude a more
prominent oligoclonality in individual mice engrafted with a lower




Figure 2. Correction of the SCID-X1 Phenotype in Il2rg-Deficient Mice
(A–C) Reconstitution of T, B, NK, and myeloid cells in the bone marrow (A), peripheral blood (B), and spleen and thymus (C) of Rag2//Il2rg/ mice transplanted with wild-
type C56Bl6 Lin cells transducedwith a PGK-GFP vector (WT + PGK-GFP), Il2rg/ Lin cells transduced with the PGK-GFP vector (KO+PGK-GFP), and Il2rg/ Lin cells
transduced with the EFS-IL2RG vector (KO + EFS-IL2RG), 6 months after transplantation. Data are presented as individual animals and as means ± SEM. Statistical dif-
ferences are expressed as follows: n.s., non-significant; **p < 0.01, ***p < 0.001, and ****p < 0.0001.
www.moleculartherapy.orgalso in the three transduction groups analyzed as individual pools,
despite the necessarily lower number of IS per sample (Figure S7).
Notably, the top 10 most abundant ISs by read count were different
in the BM and PB, and they included both intragenic and intergenic
events (Figure 4C).
Interestingly, the proportion of intragenic (intronic + exonic) ISs was
significantly decreased in the post-transplant samples with respect to
the pre-transplant Lin sample (65% in both the BM and PB versus
72% in Lin cells, c2 test p value < 0.0001) (Figure 4B), suggesting
a negative selection of cells carrying an intragenic LV insertion in vivo.
The difference was significant also when considering only the integra-
tions in exons (3.6% in the BM and 3.4% in the PB versus 4.5% in Lin
cells, p = 0.002) (Figure 4B). When analyzed in individual transduc-
tion groups, the difference remained significant except for the
16-week group (69.1% in the BM and 68.7% in the PB versus 71.3%
in pre-transplant cells, p = 0.14), where the relatively low number
of post-transplant integrations may have affected the significance of
the test. Most of the post-transplant ISs were not found in the large
pool of pre-transplant ISs (98% and 87% in the BM and PB samples,Molecurespectively; Figure 4D), while, as expected, a significant fraction of
ISs was shared between the post-transplant BM and PB pools (635
of 2,525 BM and 2,924 PB ISs or 25% and 22%, respectively;
Figure 4D).
Overall, the intragenic ISs targeted 1,305 and 1,445 genes in the post-
transplant BM and PB samples, respectively, 93% of which were in
common with those targeted in the pre-transplant, Lin cells (Fig-
ure 4E). Uniquely targeted genes were 96 in the BM and 104 in the
PB, all hit by one IS, except the Sspn gene that was targeted by 2
ISs. By applying the gene definition that includes 50 kb upstream of
the TSS, we identified 2,496 and 2,702 target genes in the BM and
PB, respectively, 93% of which were again in common with those tar-
geted in pre-transplant cells using the same definition (Figure 4F). To
determine whether any gene was targeted at a different frequency in
post- versus pre-transplant cells, we calculated an expected targeting
frequency for each gene by multiple (1,000) random sampling of a
comparable number of integrations from the corresponding pre-
transplant IS collection. We observed no significant difference be-
tween observed and expected targeting frequency for any gene inlar Therapy: Methods & Clinical Development Vol. 9 June 2018 261
Figure 3. In Vitro Immortalization Assay
Insertional mutants are identified by clonal outgrowth on a
replating assay, where non-immortalized cells do not grow
(negative, below detection limit). The number of positive
wells is used to calculate the replating frequency (RF) ac-
cording to Poisson statistics. Positive assays above the Q1
level (replating frequency [RF] of 3.17  104) are counted
as positive. Each dot represents one assay. Control data
(MOCK, RV.SF, and LV.SF) from previous experiments
conducted under the same standard operation procedure
are included. Darker colors mark the actual assays and
lighter colors indicate the meta data. Bars show the mean
RF. Above the graph, the ratio of assays above and below
the Q1 level are given together with a statistical analysis on
the incidence of positive and negative plates. EFS-IL2RG
had a significantly lower mutagenic potential compared to
RV.SF and was indistinguishable from MOCK. (NS, not
significant; ***p < 0.001 and *p < 0.05, Fisher’s exact test
with Benjamini-Hochberg multiple comparison correction).
Molecular Therapy: Methods & Clinical Developmentthe post- versus pre-transplant samples (p > 0.05) after Bonferroni
correction for false discovery rate, regardless of the gene definition.
Similarly, we observed no significant enrichment of gene ontology
(GO) categories or KEGG pathways in post-transplant samples by
running a DAVID analysis using the corresponding pre-transplant
gene lists as background. These results indicate no positive or negative
selection in vivo for cells carrying integrations in specific genes or
class of genes.
IS Analysis in Individual Animals
Mice 169 and 170, showing the CD4+/CD8+ double-positive cell pop-
ulation in the PB, and a control mouse (179) belonging to the same 2-
to 4-week transduction group, were analyzed individually. The IS
analysis revealed a polyclonal hematopoietic reconstitution, with
347 and 405 ISs retrieved from the BM of mice 169 and 170 and
1,135 ISs from mouse 179 (Figure 5). None of the most abundant
ISs (>1% of the total reads) was shared between mice 169 and 170,
although two different ISs targeted the same gene (Runx1t1)
20,283 bp apart in opposite orientation (Figure 5). Eight and 12 ISs
represented >80% of the reads in the BM of mice 169 and 170, respec-
tively, indicating substantial clonal skewing, while in mouse 179 the 8
most abundant ISs accounted for only 30% of the total reads, indi-
cating a more polyclonal and more balanced clonal composition in
this animal. None of the most abundant ISs in the PB was in common
between mice 169 (14 ISs) and 170 (11 ISs), arguing against the hy-
pothesis that the CD4+/CD8+ double-positive cell populations origi-
nated from an integration-driven clonal expansion. We were unable
to separately analyze the two cell populations to formally prove this
point or to show whether they originated from donor, transduced
cells.
To further analyze the clonal composition in the hematopoiesis of
mice 169, 170, and 179, we analyzed the ISs in the BM of secondarily
transplanted Il2rg/mice. As described above, each primary BMwas262 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20transplanted in two recipient mice, termed S1 and S2 (Figure 5A). As
expected, we retrieved substantially less ISs in the secondary
BMs (22–213) compared to the primarily transplanted animals
(347–1,135). In all recipient mice, however, the most abundant ISs
were essentially the same observed in the corresponding donor BM,
although with a somewhat different relative proportion, with mice
receiving the BM 179 having a practically overlapping IS profile (Fig-
ure 5B). These results argue against any integration-driven clonal
expansion in mice 169 and 170, even in the condition of reduced
stem cell numbers and stressed hematopoiesis. Of note, the propor-
tion of intragenic integrations further decreased in BM cells from
secondarily transplanted animals (from 67% of 1,919 ISs in the three
primary recipients to 42% of 500 ISs in the six secondary recipients,
p = 0), indicating a pronounced counterselection of cells harboring
an intragenic provirus upon serial transplantation.
A Different Set of Genes Is Targeted by Lentiviral Integration in
Human and Murine HSPCs
To gain insight into the differences in integration profiles in murine
Lin cells coming from mice of different age groups or between WT
and Il2rg-deficient Lin cells, we defined the sets of genes preferen-
tially targeted by the vector in each cell type by comparing the actual
targeting frequency of each gene with an expected targeting frequency
obtained by multiple sampling of a set of random computational ISs,
setting the threshold p value at < 0.001. By this analysis, we identified
148, 214, and 155 over-targeted genes of the 5,997, 6,599, and 5,723
genes targeted by the vector in the 2- to 4-, 5- to 10-, and 16-week
Il2rg/ Lin cells, respectively. Most of the over-targeted genes
were shared among the three age groups, with 63 genes common to
all groups (Figure 6A). We then generated a set of 22,570 EFS-
IL2RG ISs in Lin cells obtained from the BM of 8-week-old, WT
C57BL/6J mice, which we compared with the datasets obtained in
the three groups of pre-transplant Il2rg/ cells (28,886 ISs in 2- to





Figure 4. Integration Profile of the EFS-IL2RG Vector
(A) Scheme of the vector integration analysis study. ISs
were retrieved by LM-PCR and Illumina high-throughput
sequencing in pre-transplant Lin cells and post-trans-
plant BM and PB of Rag2//Il2rg/ mice transplanted
with and Il2rg/ Lin cells transduced with the EFS-
IL2RG vector (see Figure 1). (B) Genomic distribution of
the vector ISs in pre- and post-transplant cells. The sta-
tistical significance of the difference in the percentage of
intragenic (intronic + exonic) ISs in pre- versus post-
transplant cells is calculated by a c2 test. ****p < 0.0001.
(C) Histograms of the percentage of sequence reads
associated to each IS in the pre- and post-transplant cells.
In each bar, the fraction of ISs with read count <1% is
shown in gray, while ISs with read counts >1% are shown
in different colors. The top 10 most abundant ISs in each
sample are identified by their genomic coordinates. (D)
Venn diagram showing the number of ISs identified in pre-
and post-transplant cells. (E) Venn diagram showing the
number of target genes identified in pre- and post-trans-
plant cells by applying a stringent gene definition (from
the +1 nt to the gene end). (F) Venn diagram showing the
number of target genes identified in pre- and post-trans-
plant cells by applying an enlarged gene definition, which
includes 50 kb upstream of the +1 nt.
www.moleculartherapy.orgstatistical analysis identified a set of 89 over-targeted genes in WT
cells, the majority of which (58%–73%) were shared with the set of
genes over-targeted in Il2rg/ cells (Figure 6A), indicating that the
vector identifies essentially the same preferential target genes in
WT and Il2rg-deficient hematopoietic progenitors.
To compare the integration characteristics of LV vectors in murine
versus human cells, we compared the integration profile of the EFS-
IL2RG vector in murine Lin cells with that obtained by transducing
with the same vector granulocyte colony-stimulating factor (G-CSF)-
mobilized PB CD34+ HSPCs. From these cells, we retrieved 25,682 ISs
targeting 6,498 genes, 247 of which were significantly over-targeted.
We also analyzed larger datasets previously obtained from BM- or
umbilical cord blood-derived derived HSPCs transduced with an
LV expressing the human WAS gene18 or a GFP gene30 in the same
CCL-SIN-18-WPRE backbone, which identified 337 and 741 over-Molecular Therapy: Methodstargeted genes, respectively (Table 2). While a
substantial number of over-targeted genes was
in common between the two adult human cell
samples, almost 60% of the genes over-targeted
in CB-derived HSPCs were specific for this cell
type (Figure 6B). Interestingly, when we
compared the genes preferentially targeted in
murine Lin cells with the human orthologs
(NCBI HomoloGene definition) over-targeted
in human mobilized CD34+ cells, we found
only one gene in common (ARAP2). The
comparison with the other two human datasets
showed again no similarity (Figure 6C). Table S4lists the top 50 over-targeted genes in murine Lin cells and human-
mobilized CD34+ cells ranked by number of ISs. The human list
contains most of the genes found frequently targeted in pre- and
post- transplantation samples in recent LV-based human gene ther-
apy trials (e.g., KDM2A, PACS1, NPLOC4, GPATCH8, ASH1L,
and FCHSD2),17,18,20,31 none of which is targeted at any significant
frequency in murine progenitors. These data show substantial differ-
ences in the pool of genes targeted at high frequency by LVs inmurine
versus human cells, which may potentially impact on the predictivity
of LV-driven perturbation of specific genes in mouse studies.
DISCUSSION
The current therapy for SCID-X1 is transplantation of CD34+ HSPCs
from histocompatible donors. The efficacy of the therapy depends on
age, availability of a suitable donor, and absence of infections at the
time of treatment.32 Selective advantage allows donor progenitor cells& Clinical Development Vol. 9 June 2018 263
A
B
Figure 5. Integration Site Analysis in Individual Mice
(A) Scheme of the vector integration study in three individualRag2//Il2rg/mice transplanted with and Il2rg/ Lin cells transduced with the EFS-IL2RG vector (169, 170,
and 179) and the corresponding, secondarily transplanted Il2rg-deficient mice. (B) Clonal composition in the BM of secondarily transplanted mice compared to that of the
parental mice. The total number of ISs retrieved in each sample is shown on the top of the histograms, while the percentage of sequence reads associated to each ISs is
indicated in gray (<1% of the total) or in different colors (>1% of the total). For the intragenic ISs, the name of the targeted gene is reported in the colored portion of the bar.
Intergenic ISs are identified by NA followed by the genomic coordinates.
Molecular Therapy: Methods & Clinical Developmentto repopulate the patient’s lymphopoietic organs even in the absence
of marrow conditioning, which is traditionally avoided to reduce
treatment toxicity. However, non-T immune cell reconstitution is
variable in the absence of myeloablation, reducing the overall efficacy
of the therapy. Gene therapy, i.e., transplantation of genetically cor-
rected, autologous HSPCs, reduces the risk associated with allogeneic
transplantation and is theoretically accessible to all patients irrespec-
tive of donor availability. The first trials proved the efficacy of the
therapy in reconstituting T cell immunity in pediatric patients, and
they showed that the absence of marrow conditioning impairs recon-
stitution of B and NK cell immunity also in an autologous setting.3,6,10
Gene therapy was only partially efficacious in older patients, probably
due to involution of niches for new T cell development.33
To improve the efficacy of gene therapy, several groups developed LV
vectors expressing IL2RG, and they attempted to introduce non-mye-
loablative conditioning to allow for a better clinical response.23,27,34264 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20We developed a SIN lentiviral vector, EFS-IL2RG, expressing a
codon-optimized cDNA driven by the constitutive EFS promoter,
which showed no tendency for insertional gene activation in preclin-
ical models35–37 and in clinical trials for ADA-SCID. We show recon-
stitution of T, B, and NK cells in sub-lethally irradiated IL2rg//
Rag2/ mouse transplanted with IL2rg/ Lin HSPCs transduced
with the EFS-IL2RG vector. IL2rg//Rag2/ mice completely lack
T, B, and NK cells, and they provide a better, less leaky background
to analyze immune reconstitution with respect to Il2rg/ single-
knockout mice. Gene therapy showed an efficacy comparable to
transplantation with syngeneic wild-type HSPCs, in the absence of
treatment-related adverse events. Reconstitution of B and NK cells
was lower in animals receiving gene-corrected cells compared to con-
trols, although serum immunoglobulin levels (IgM and IgG) were
comparable. The good performance of the vector was confirmed by
the high proportion (>80%) of gene-marked clonogenic progenitors




Figure 6. Genes Over-Targeted by the EFS-IL2RG in Human and Murine HSPCs
(A) Venn diagrams showing the number of genes over-targeted by EFS-IL2RG in Lin cells obtained from the BM of both wild-type and Il2rg-deficient mice of different age
groups. (B) Over-targeted genes in common between humanCD34+ HSPCs obtained from adult bonemarrow, umbilical cord blood, andG-CSF-mobilized peripheral blood.
(C) Over-targeted homologous genes in common between murine Lin and human-mobilized CD34+ HSPCs. Only one gene (ARAP2) is over-targeted by EFS-IL2RG in both
populations.
www.moleculartherapy.orgEFS-IL2RG at an MOI of 100. Overall, the study shows the potential
of the EFS-IL2RG vector in correcting SCID-X1 after non-myeloabla-
tive conditioning.
Vector IS analysis carried out at the end of the study showed that BM
repopulation was sustained by a largely polyclonal repertoire of he-
matopoietic stem cells (HSCs), with no signs of vector-driven clonal
dominance and no significant selection of cells carrying integration in
specific genes, as evaluated after pooling BM and PB cells from ani-
mals receiving the same transduced cell batches. This type of analysis
averages engraftment efficiency and estimates clonal representation,
although it cannot exclude oligoclonality in individual mice with
very low chimerism. Interestingly, we observed a reduction in intra-
genic integrations in BM and PB cells in primary and even more in
secondary transplant recipients with respect to pre-transplant Lin
cells, indicating either a different integration bias in repopulating
HSCs with respect to a progenitor cell pool or a negative in vivo selec-
tion of cells carrying integrations in exons and introns. Integrations in
exons cause mono-allelic gene knockout, while the presence of LVMolecuproviruses in introns may induce post-transcriptional alterations of
gene expression through the insertion of splicing and polyadenylation
signals in primary transcripts, as previously shown in human hemato-
poietic cells.38,39 Our data suggest that these integration events may
reduce cell fitness in vivo and be counterselected when occurring in
repopulating HSCs. However, we did not observe significant differ-
ences in the categories of genes targeted by LV integration before
and after transplantation, indicating that, if intragenic integrations
cause a reduction of cell fitness, they do so in a relatively random
fashion.
We observed an immature, CD4+/CD8+ double-positive T cell popu-
lation in the peripheral circulation of two transplanted mice, which
disappeared upon secondary transplantation, indicating their non-
malignant nature and/or lack of repopulating capacity. Vector IS
analysis showed that the two animals, as well as a control animal
transplanted with the same batch of transduced cells at the same
age, were engrafted by a polyclonal HSC cell population that further
engrafted secondary recipients in a similar relative proportion, withlar Therapy: Methods & Clinical Development Vol. 9 June 2018 265
Table 2. Summary of Integration Data in Human CD34+ HSPCs from Different Sources
HSPCs ISs Intergenic ISs (%) Intronic ISs (%) Exonic ISs (%) Targeted Genes Over-targeted Genes (p < 0.001) ISs (Range)
BM CD34+ 37,423 22.60 72.50 4.80 7,425 337 1–70
CB CD34+ 58,294 19.40 75.60 5.00 8,911 741 1–207
PB CD34+ 25,682 21.20 74.30 4.50 6,498 247 1–61
BM, bone marrow; CB, umbilical cord blood; PB, mobilized peripheral blood.
Molecular Therapy: Methods & Clinical Developmentno evidence of expansion of clones carrying integration in specific
genes. On the contrary, cells carrying integrations in potential
proto-oncogenes, such as Runx1t1, Clcn5, or Tpk1, either disappeared
or were less prevalent in secondary versus primary recipients, indi-
cating a random fluctuation of stem cell clones independently from
the provirus insertion site. Together with the results of the IVIM,
the in vivo vector integration analysis demonstrates the favorable
genotoxic profile of the EFS-IL2RG vector.
The EFS-IL2RG vector showed a statistically significant over-target-
ing of a set of genes with no obvious characteristics in terms of size,
gene expression activity, or function. Integration into hotspots is a
typical feature of LV vectors reported in pre- and post-transplant he-
matopoietic cells in several clinical studies,17–22 which depends on the
topological distribution of euchromatin in the membrane-proximal
compartment of the cell nucleus, favored by lentiviral integration.15
Interestingly, the set of genes targeted by EFS-IL2RG in murine
Lin cells was completely different from that targeted in human
CD34+ cells obtained from BM, mobilized PB, or umbilical cord
blood, suggesting a very different topological organization of
homologous genes in HSPCs, and most likely in repopulating stem
cells, between mice and humans. This evidence suggests that mouse
models may not be entirely predictive of the genotoxic consequences
of lentiviral integration when analyzing events happening in specific
genes or gene clusters, due to the exceedingly different targeting fre-
quency between the two species.
Overall, this study paves the way for application of an improved
lentiviral gene therapy for SCID-X1. Combined with state-of-the-
art cell processing and increased automation, the vector described
in the study offers a clear potential for commercial drug
development.
MATERIALS AND METHODS
Vector Production and Titration
Lentiviral vectors pCCL_pEF1a_IL2RGWT_WPRE* and pCCL_
pEF1a_IL2RGcoWPRE* (EFS-IL2RG) were designed and generated
at Hannover Medical School, and they were packaged by triple trans-
fection of HEK293T cells with the CMV-GAG/POL, CMV-REV, and
CMV-VSV-G plasmids in 225-cm2 tissue culture flasks. The superna-
tants were collected 48 hr post-transfection, concentrated by ultra-
centrifugation, and resuspended in X-VIVO 20 medium (Lonza).
For the animal study, EFS-IL2RG was produced by transfecting
HEK293T cells at a 50-l scale in CF10 cell factories, purified by266 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20ion-exchange chromatography, concentrated by tangential-flow
filtration, and formulated in X-VIVO 20, as previously described.40
The viral titer was calculated by transduction of the human colorectal
carcinoma cell line (HCT116) with serial dilution of the viral prepa-
ration followed by qPCR, as previously described.41
Transduction of Human Cells
The ED7R cell line was derived from an adult human T cell leukemia
lacking IL2RG expression.42,43 ED7R cells were grown in RPMI-1640
medium supplemented with 10% fetal calf serum, penicillin/strepto-
mycin, and Glutamax (all from Gibco). 5  105 ED7R cells
were transduced at an MOI of 0.1–100 for 6 hr with polybrene
(6 mg/mL, Sigma-Aldrich) and maintained in culture for 12 days.
IL2RG expression was analyzed by flow cytometry.
CD34+ cells were isolated from cord blood or G-CSF-mobilized PB
samples provided by the Centre Hospitalier Sud Francilien (Evry,
France) or the Institut Gustave Roussy (Paris, France), under full
informed consent. CD34+ cells were immunoselected with the
CliniMACS system (Miltenyi Biotec), following the manufacturer’s
instructions; pre-activated by overnight culture in X-vivo 20 (Lonza)
containing 25 ng/mL human stem cell factor (SCF; CellGenix),
50 ng/mL human Flt-3 ligand (CellGenix), 25 ng/mL human
thrombopoietin (TPO; CellGenix) ,and 10 ng/mL human IL-3
(CellGenix); and transduced at differentMOIs for 6 hr in the sameme-
dium in the presence of 4 mg/mL protamine sulfate (Sigma-Aldrich).
After transduction, cells were washed and maintained in liquid culture
in the activation medium or grown as individual progenitors in semi-
solid Methocult medium (H3434, STEMCELL Technologies) for
2 weeks. Individual colonies were counted and harvested for VCN
determination after 2 weeks of culture.
Transduction of Murine Lin– Cells
Lin cells were purified from the BM of Il2rg/ male mice by
magnetic bead cell sorting (Miltenyi Biotec) and activated overnight
in X-vivo 20 supplemented with 50 mg/mL penicillin, 50 ng/mL
streptomycin, 20 ng/mL murine interleukin-3 (Miltenyi Biotec),
100 ng/mL human TPO (CellGenix), 100 ng/mL human Flt-3 ligand
(CellGenix), and 100 ng/mLmurine SCF (Miltenyi Biotec). Cells were
transduced with the CCL-EF1a-coILRG-WPRE or the CCL-PGK-
GFP-WPRE vector at an MOI of 100 for 6 hr in the presence of
6 mg/mL protamine sulfate (Sigma-Aldrich). Cells receiving two
rounds of infection were washed and re-exposed overnight to the vec-
tor under the same conditions.18
www.moleculartherapy.orgTransplantation of Il2rg-Deficient Mice
Mice were housed at the Genethon animal facility in accordance with
national and European ethical guidelines, following the animal study
protocol DAP 2014-005-A. BM cells were flushed from femurs and
tibias of C57Bl6 mice (from Charles River Laboratories), Il2rg/
mice (B6.129S4-Il2rgtm1Wjl/J, from Charles River Laboratories),
and Rag2//Il2rg/ mice (B6-Rag2/tm1Fwa/Il2rg/tm1Wjl, from
Taconic). Transduced Lin cells (5  105 cells/mouse) were admin-
istered intravenously by retro-orbital injection to Rag2//Il2rg/
female mice that were given 6-Gy total body irradiation as a single
exposure 3 hr before transplantation.Analysis of VCN, Chimerism, and IL2RG Expression
Genomic DNA was extracted from transduced cells expanded in
liquid culture by the Wizard genomic DNA purification kit
(Promega). DNA from colonies was extracted after lysis with protein-
ase K (Thermo Fisher Scientific) under standard conditions. The
average VCN per cell (VCN/cell) was analyzed by duplex Taqman
qPCR with primers and probes annealing to the HIV psi sequence
and a reference gene, the human ALB or the murine Ttn gene. Results
were calculated based on a standard curve of a plasmid containing the
two sequences. Donor cell chimerism was measured by Taqman
qPCR with primers specific for the murine Y chromosome and Ttn
as a normalizer gene. Results were expressed as percentage of male
cells in the total cells, based on a reference titration curve consisting
of different proportions of male/female blood cells. All PCRmeasure-
ments were performed at least in duplicates in an ABI PRISM 7700
system (Thermo Fisher Scientific). Total RNA was extracted with
the SV Total RNA Isolation System (Promega), reverse transcribed
into cDNA with the Super-Script II RT (Gibco) using random hex-
amer primers, and amplified with the TaqMan Universal PCRMaster
Mix (Thermo Fisher Scientific) on an ABI PRISM 7700 sequence de-
tector (Thermo Fisher Scientific). Vector-derived IL2RG mRNA was
measured by qRT-PCR in duplicates with primers annealing to
WPRE and the human or murine TFIID gene as a normalizer. All
primers and probes are listed in the Supplemental Materials and
Methods.Flow Cytometry
Cells were resuspended in PBS and incubated for 30 min at 4C with
antibodies for specific antigens or with isotype control, following the
manufacturer’s instructions. Stained cells were washed and measured
on a BD LSR II flow cytometer (BD Biosciences). Analyses were per-
formed with the FlowJo software version (v.)7.6.5. The complete list
of antibodies used in the study is in the Supplemental Materials
and Methods.Statistical Analysis
Statistical analyses of the results of the animal study were performed
using GraphPad Prism v.7.0 for Windows. Results are reported as
mean ± SEM. Statistical differences between means were evaluated
by Mann-Whitney or c2 test as appropriate. Differences were consid-
ered significant at a p value < 0.05.MolecuIVIM Assay
The IVIM assay was performed as previously described.28,29,44 Briefly,
1  105 Lin BM cells from C57BL/6J mice were transduced with
gammaretroviral or lentiviral vectors, expanded for 15 days, and
seeded on 96-well plates (100 cells/well). After a further incubation
for 2 weeks, insertional mutants were detected by microscopic evalu-
ation or absorbance measurement of a reduced formazan (MTT
assay) in a microplate reader.45 Positive wells were counted and the
replating frequencies (RFs) calculated by the R package limdil.46
Plates with an RF R 3.17  104 were defined as positive assays.
The incidence of positive assays was compared by a Fisher’s exact
test with Benjamini-Hochberg correction for multiple comparisons.
For selected clones,Mecom gene expression was analyzed as described
in the Supplemental Materials and Methods.
Vector IS Analysis
30 LTR vector-genome junctions were amplified by LM-PCR. Briefly,
0.3–2 mg genomic DNA was digested 6 hr at 37C with the Tru91 re-
striction enzyme (Roche), purified by NucleoSpin Gel and PCR
Clean-up kit (MACHEREY-NAGEL), and ligated overnight to a
TA-protruding double-stranded DNA linker by T4 DNA Ligase
(New England Biolabs). Ligated DNA was purified, digested over-
night at 37C with SacI (Roche), and purified again. Multiple nested
PCRs (10–20) were performed with specific primers annealing to the
linker and the 30 vector LTR, adapted to Illumina sequencing and
containing a 4-bp sample-specific bar code for sample identification.
The pre-transplant Lin cell library was derived from a pool of DNAs
collected from cells transduced by 1 or 2 hits (1 mg each). The post-
transplant libraries were derived from pools of DNAs from individual
mice in each transduction group or from DNAs of individual primar-
ily or secondarily transplanted mice. Libraries were quantified on a
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific), and
they were loaded onto a 1% agarose gel for amplicon size selection.
Amplicons ranging from 200 to 500 kb were manually extracted
from the gel and purified by NucleoSpin Gel and PCR Clean-up kit.
About 1 mg of the final libraries was subsequently processed with
MiSeq Reagent Kit v3 (2  300-bp pair-end sequencing), following
the manufacturer’s instructions adding a 6-bp sample-specific index,
and sequenced to saturation on an Illumina MySeq machine at IGA
Technology Services (Udine, Italy). ISs in human cord blood-derived
and adult BMCD34+ cells were determined by re-analyzing raw reads
from previously published studies.18,30
Raw reads from Illumina paired-end sequencing were bio-
informatically trimmed to recover the host genome sequences adja-
cent to the 30 proviral LTR by the Skewer software (mismatch rate
of 0.12, minimal length of 20 bp after trimming, and a minimal match
length equal to the pre-trimming sequence), and they were mapped
on the reference genome (human GRCh37.75/hg19 and murine
GRCm38/mm10) by the Bowtie2 software (>95% identity). The se-
quences are available at GenBank Sequence Read Archive (SRA):
SRP135780. The genomic coordinates of the first nucleotide in the
host genome adjacent to the viral LTR were indicated as IS. ISs orig-
inated by different reads mapping in the same genomic position werelar Therapy: Methods & Clinical Development Vol. 9 June 2018 267
Molecular Therapy: Methods & Clinical Developmentcollapsed, recovering the number of corresponding reads (read
count). Unique ISs were annotated on the RefSeq gene database as in-
tergenic or intragenic (exonic or intronic). Genes (defined by themost
upstream TSS to the most downstream 30 end) hosting at least one IS
were identified as target genes. Genes with targeting frequency signif-
icantly higher than random, defined by 200 random sampling of vir-
tual ISs corresponding to 5,330,124 and 5,812,911 Tru91 sites in the
human and murine genome, respectively, were defined as over-tar-
geted after Bonferroni correction of the p values for false discovery
rate. Genes with at least 3 ISs and a Bonferroni-corrected p value
of < 0.001 were defined as over-targeted. To compare over-targeted
genes in the human and murine genomes, we retrieved the orthologs
genes by the HomoloGene tool on the NCBI webpage https://www.
ncbi.nlm.nih.gov/homologene/statistics. Additional information
about the bioinformatics processing of the sequencing reads can be
found in the Supplemental Materials and Methods.
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